Unicycive Therapeutics Inc (NASDAQ:UNCY) price on current trading day, rose 8.91% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.51.
A look at the stock’s price movement, the close in the last trading session was $0.47, moving within a range at $0.4502 and $0.5346. The beta value (5-Year monthly) was 2.147. Turning to its 52-week performance, $1.39 and $0.20 were the 52-week high and 52-week low respectively. Overall, UNCY moved -11.85% over the past month.
Unicycive Therapeutics Inc’s market cap currently stands at around $61.29 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-30.
Turning to the stock’s technical picture we see that short term indicators suggest on average that UNCY is a Hold. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend UNCY as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
UNCY’s current price about -12.42% and -11.25% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.17, while 7-day volatility ratio is 16.93% and 10.69% in the 30-day chart. Further, Unicycive Therapeutics Inc (UNCY) has a beta value of 2.10, and an average true range (ATR) of 0.06.
If we refocus on Unicycive Therapeutics Inc (NASDAQ:UNCY), historical trading data shows that trading volumes averaged 1.58 over the past 10 days and 1.04 million over the past 3 months. The company’s latest data on shares outstanding shows there are 113.84 million shares.
The 17.08% of Unicycive Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 53.77% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.52 million on 2025-03-14, giving us a short ratio of 1.93. The data shows that as of 2025-03-14 short interest in Unicycive Therapeutics Inc (UNCY) stood at 157.00001 of shares outstanding, with shares short rising to 0.8 million registered in 2025-02-14. Current price change has pushed the stock -35.53% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the UNCY stock continues to rise going into the next quarter.
